Baba Ishfaq Ahmad, Wani Zubair Ahmad, Ali Shazia, Ahmad Zahoor, Mubarak Mohamad Mosa
Clinical Microbiology PK/PD Division, CSIR - Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, 190005, India.
Curr Top Med Chem. 2024 Mar 11. doi: 10.2174/0115680266282919240224130345.
The urgent need for novel antibiotics in the face of escalating global antimicrobial resistance necessitates innovative approaches to identify bioactive compounds. Actinomycetes, renowned for their prolific production of antimicrobial agents, stand as a cornerstone in this pursuit. Their diverse metabolites exhibit multifaceted bioactivities, including potent antituberculosis, anticancer, immunomodulatory, immuno-protective, antidiabetic, etc. Though terrestrial sources have been exploited significantly, contemporary developments in the field of antimicrobial drug discovery have put marine actinomycetes in a prominent light as a promising and relatively unexplored source of novel bioactive molecules. This is further boosted by post-genomic era advances like bioinformatics-based secretome analysis and reverse engineering that have totally revitalized actinomycetes antibiotic research. This review highlights actinomycetes-based chemically diverse scaffolds and clinically validated antibiotics along with the enduring significance of actinomycetes from untouched ecosystems, especially with recent advanced techniques in the quest for next-generation antimicrobials.
面对全球抗菌药物耐药性不断升级，对新型抗生素的迫切需求使得识别生物活性化合物的创新方法成为必要。放线菌以其大量产生抗菌剂而闻名，是这一探索的基石。它们多样的代谢产物具有多方面的生物活性，包括强效抗结核、抗癌、免疫调节、免疫保护、抗糖尿病等。尽管陆地来源已得到大量开发，但抗菌药物发现领域的当代发展使海洋放线菌成为一种有前景且相对未被充分探索的新型生物活性分子来源，备受关注。基于生物信息学的分泌组分析和逆向工程等后基因组时代的进展进一步推动了这一趋势，这些进展彻底振兴了放线菌抗生素研究。本综述重点介绍了基于放线菌的化学结构多样的支架和临床验证的抗生素，以及来自未受干扰生态系统的放线菌的持久重要性，特别是在寻求下一代抗菌药物过程中利用的最新先进技术。
